歌礼制药-B宣布，其口服小分子药物ASC36_35固定剂量复方（FDC）的临床前研究数据，将在第62届欧洲糖尿病研究协会（EASD）年会上进行口头讨论。数据显示，该药物在减重方面表现出优于艾拉兰肽（Eli Lilly旗下药物）与替尔泊肽（Tirzepatide）联合疗法的潜力。
这项研究结果的展示，标志着歌礼制药在代谢疾病治疗领域，特别是针对肥胖症的新型口服疗法开发上，取得了重要进展。ASC36_35 FDC作为一种口服制剂，若其疗效在后续临床试验中得到证实，将为患者提供比现有注射疗法更为便捷的治疗选择。
数据将在国际权威学术会议上进行深入探讨，这有助于科学界和产业界更全面地评估该候选药物的前景及其对现有治疗格局的潜在影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.